Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
1681.HK
Strong BuyUnloved QualityAPPROVEConsun Pharmaceutical Group Limited · Healthcare · China · $1.5B · Avg Vol: $3M/d
The company meets eligibility requirements with all scores above 60 and shows management conviction through sustained insider buying and an active share buyback program.
COMPANY DESCRIPTION
Consun Pharmaceutical Group Limited is a research-driven pharmaceutical company in China focused on the development, manufacturing, and sale of modern Chinese medicines and Western drugs, particularly in nephrology and orthopedics. It benefits from a specialized focus on niche therapeutic areas, where it has developed proprietary and well-recognized products with strong market penetration within China's healthcare system. Consun is a leading pharmaceutical company in specific therapeutic categories within China, leveraging its R&D capabilities.
FINANCIAL SUMMARY (HKD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.4B | 2.7B | 3.0B | 3.5B | 4.0B | 13.7% | 4.3B | 4.5B | 5.1B | 12.8% |
| EPS (HKD) | 0.87 | 1.01 | 1.16 | 1.30 | 1.49 | 14.5% | 1.46 | 1.73 | 1.90 | 13.2% |
| Shares | 824.2M | 807.0M | 792.4M | 849.4M | 840.1M | +1.9% | 839.0M | — | — | — |
| Debt | 715.3M | 538.7M | 598.9M | 312.8M | 249.3M | -23.2% | 268.7M | — | — | — |
| Equity | 3.1B | 3.7B | 4.2B | 4.8B | 5.3B | 14.7% | — | — | — | — |
| Op CF | 849.4M | 1.1B | 958.8M | 1.3B | 1.4B | 13.7% | 1.4B | — | — | — |
| Inv CF | -349.2M | -431.8M | -271.3M | -218.8M | -2.5B | — | — | — | — | — |
| Fin CF | -195.1M | -400.6M | -327.9M | -853.8M | -833.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 1681.HK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 1681.HK | Consun Pharmaceutical Group Limited(you) | $1.5B | 98 | Strong Buy |
| 600572.SS | Zhejiang CONBA Pharmaceutical Co.,Ltd. | $1.7B | 95 | Strong Buy |
| 600267.SS | Zhejiang Hisun Pharmaceutical Co., Ltd. | $2.1B | 98 | Strong Buy |
| 600993.SS | Mayinglong Pharmaceutical Group Co., Ltd. | $1.5B | 89 | Strong Buy |
| 600420.SS | Shanghai Shyndec Pharmaceutical Co., Ltd. | $1.7B | 92 | Strong Buy |
| 000989.SZ | Jiuzhitang Co., Ltd. | $1.2B | 93 | Strong Buy |
| 000915.SZ | Shandong Wit Dyne Health Co.,Ltd. | $873M | 98 | Strong Buy |
| 600479.SS | ZhuZhou QianJin Pharmaceutical Co.,Ltd | $976M | 96 | Strong Buy |
| 002332.SZ | Zhejiang Xianju Pharmaceutical Co., Ltd. | $1.3B | 91 | Strong Buy |
| 600211.SS | Tibet Rhodiola Pharmaceutical Holding Co. | $1.9B | 91 | Strong Buy |
Peer medians: ROE 4.4% · P/E 28.1x · Gross margin 53.1%